Onecrea Medical

Executive Summary

Onecrea Medical is a private, pre-clinical stage medical device company based in San Diego, California, focused on developing a next-generation transcatheter aortic valve replacement (TAVR) system. Founded in 2018, the company leverages patented technology from the Cleveland Clinic to create a device aimed at improving outcomes for patients with aortic stenosis. Onecrea's TAVR is designed to address limitations of current-generation valves, such as paravalvular leak, valve durability, and deployment precision. The company is currently in the pre-clinical phase, conducting bench testing and animal studies to validate its technology before moving toward first-in-human trials. With a strong intellectual property portfolio and a seasoned team, Onecrea is positioned to compete in the rapidly growing TAVR market, which is projected to exceed $10 billion by 2030. However, as a pre-clinical company with no disclosed funding rounds, the path to commercialization will require significant capital investment and successful clinical validation. The company represents an early-stage opportunity in a high-demand therapeutic area, though substantial execution risk remains.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round70% success
• Q1 2027First-in-human study initiation40% success
• Q4 2026FDA breakthrough device designation60% success